A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Sotagliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SOTA-MET
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 13 Mar 2020 Planned number of patients changed from 500 to 1000.
- 26 Jul 2019 According to a Lexicon Pharmaceuticals media release, primary endpoint (Change from Baseline in HbA1c) has been met.
- 26 Jul 2019 According to a Lexicon Pharmaceuticals media release, data will be presented at upcoming medical conferences.